Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Cash & Equivalents (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Cash & Equivalents for 2 consecutive years, with $137.5 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 148.68% to $137.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $137.5 million through Dec 2025, up 148.68% year-over-year, with the annual reading at $137.5 million for FY2025, 148.68% up from the prior year.
  • Cash & Equivalents hit $137.5 million in Q4 2025 for Xilio Therapeutics, up from $103.8 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $137.5 million in Q4 2025 to a low of $34.0 million in Q1 2024.